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Recent scientific advances have shown that 
antiretroviral therapy (ART) not only preserves 
the health, quality of life, and life expectancy 
of people living with HIV, but people living with 
HIV who take HIV medicine as prescribed and 
get and keep an undetectable viral load have 
effectively no risk of transmitting HIV to their 
HIV-negative sexual partners. 
These developments have transformed the 
nation’s approach to HIV prevention. By ensuring 
that everyone with HIV is aware of their infection, 
receives the treatment they need, and achieves 
sustained viral suppression, we can sharply 
reduce new infections in the United States. 
This vision is a core focus of CDC’s high-impact 
HIV prevention strategy, which aims to achieve 
the greatest possible reductions in HIV infections 
by making sure that resources go to the regions, 
populations, and prevention strategies where they 
will have the greatest impact. 
To help gauge progress towards national goals 
(see sidebar) and direct HIV prevention resources 
most effectively, CDC tracks the “HIV care 
continuum.” The continuum is the series of 
steps from the time a person receives a diagnosis 
of HIV through the successful treatment of their 
infection with HIV medications. This fact sheet 
explains the various approaches and data used to 
develop the HIV care continuum, how it is used to 
improve outcomes for people living with HIV in the 
United States, and how it helps guide the nation’s 
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National HIV/AIDS Strategy, 2020 
Objectives on HIV Diagnosis and Care 
At the national level several specific goals related 
to early HIV diagnosis and effective care include: 
90% 
Increasing the number of HIV-positive 
individuals aware of their status to 90%. 
85% 
Increasing the proportion of persons with 
newly diagnosed HIV who are linked to 
care within one month to 85%. 
80% 
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Increasing the proportion of HIV-diagnosed 
individuals whose virus is effectively 
suppressed to 80%, with an emphasis 
on youth and persons who inject drugs. 
What is the HIV Care Continuum? 
The ultimate goal of HIV treatment is to achieve viral suppression, which means the amount of HIV in the body is very 
low or undetectable. This is important for people with HIV to stay healthy, have improved quality of life, and live longer. 
People living with HIV who maintain viral suppression have effectively no risk of passing HIV to others. 







visited an HIV heath 
care provider within 
1 month (30 days) 
after learning they 
were HIV positive 
Received** or were 
retained in care*** 
received medical 
care for HIV 
infection 
Viral suppression 
their HIV “viral load” – 
the amount of HIV 
in the blood – 
was at a very 
low level.
* Linked to care is calculated differently from other steps in the continuum, and cannot be directly compared to other steps. See Table 1 on page 5 for details.
 ** Receipt of medical care was defined as ≥1 test (CD4 or viral load [VL]) in 2016. 
 *** Retained in continuous medical care was defined as ≥2 tests (CD4 or VL) ≥3 months apart in 2016. Viral suppression was defined as <200 copies/mL on the most   
 recent VL test in 2016. See Table 1 on page 5 for details. 
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Two Ways to Monitor the Continuum 
CDC currently uses two different approaches 
to monitor the HIV care continuum. The two 
approaches are used for different purposes, 
and both are essential to monitor the nation’s 
progress and identify key HIV prevention and 
care needs. 
The major difference between the two approaches is 
that they have different denominators. That is, they 
measure progress among different groups of people 
living with HIV: 
The prevalence-based HIV care continuum 
describes the number of people who are at each 
step of the continuum as a percentage of the total 
number of people living with HIV (known as HIV 
prevalence). Prevalence includes both people 
whose infection has been diagnosed and those 
who are infected but don’t know it. 
This approach allows us to monitor elements of the care 
continuum by measuring the care outcomes among all 
Americans living with HIV. It can also monitor outcomes for 
broad populations, such as African Americans or men who 
have sex with men (MSM). However, because of certain 
statistical limitations, this approach does not allow more 
segmented analyses within those populations, such as 
young black MSM. See Figure 1 for the 2016 prevalence-
based HIV care continuum. 
The diagnosis-based HIV care continuum 
shows each step as a percentage of the  
number of people living with diagnosed HIV.  
This approach gives us more detailed information about 
persons who are living with diagnosed HIV and provides a 
way to look at the continuum within subgroups of affected 
populations, for example young black MSM. For the 2016 
diagnosis-based continuum, see Figure 2. 
The difference is in the denominators • All people living with HIV (includes persons with diagnosed  
and undiagnosed infection) is used as the denominator for the prevalence-based continuum. People living 
with diagnosed HIV is the denominator used for the diagnosis-based continuum. 
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Linked to Care 
78%• In 2017, 78% of persons receiving a diagnosis of HIV were linked to care 
within 1 month. 
• Defined as linked to care within 
1 month of HIV diagnosis.
- Denominator is persons receiving a diagnosis of 
HIV in a measurement year
- Numerator is the number of persons who were 
linked to care within 1 month. 
• Because it has a different denominator, it cannot be 
directly compared to other steps in the continuum. 
See Table 1 on page 4 
for additional details
Different Approaches for Different Needs 
CDC’s current approaches draw on the best data 
available.  
It is important to know how the continuum will 
be used. Some uses of the prevalence-based 
continuum include: 
• Monitoring testing efforts in the U.S. and 
demonstrating the importance of diagnosing 
HIV infections to achieve viral suppression 
• Monitoring how the U.S. is doing among all persons 
living with HIV 
• Comparing U.S. data to other countries who monitor 
the continuum among all persons living with HIV 
Some uses of the diagnosis-based continuum include: 
• Monitoring U.S. progress in comparison to national 
2020 goals 
• Monitoring U.S. progress in comparison to the 
UNAIDS 90-90-90 goals 
• Monitoring disparities by examining data among 
sub-groups of the population 
• Monitoring data at a local level to understand local 
progress and identify additional action steps to 
meet national level goals 
Ways of presenting the continuum also will continue 
to evolve over time, as better and more complete  
data become available.  
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How CDC Develops the Continuum 
The data for both the prevalence- and diagnosis-
based continua of care approaches come from: 
The National HIV Surveillance System (NHSS), which 
provides a range of information on people who have 
diagnosed HIV or have died with HIV. Data are from  
every U.S. state and territory and the District of Columbia 
and include sex, race/ethnicity, route of transmission, 
and age. The data are reported to CDC by state and 
local health departments. This is the source of data 
for both the prevalence and diagnosis denominators. 
Data from the states and D.C. that have complete 
laboratory reporting are used to calculate some 
measures of the continuum. 
For more information, details on the two continuum 
approaches are found in Table 1 below. Some of these 
indicators are also used to monitor progress toward the 
national goals. For more information on national indicators, 
please see https://www.cdc.gov/hiv/pdf/library/factsheets/ 
cdc-hiv-national-hiv-care-outcomes.pdf. 
What is CDC doing to improve the 
outcomes at every step of the HIV 
Care Continuum? 
CDC is undertaking many initiatives including: 
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• Directly funding health departments to implement 
a comprehensive HIV surveillance and prevention 
program – to prevent new HIV infections and 
achieve viral suppression among persons living 
with HIV. The integrated approach promotes and 
supports improving health outcomes for persons 
living with HIV through achieving and sustaining viral 
suppression, and reducing health-related disparities 
by using quality, timely, and complete surveillance 
and program data to guide HIV prevention efforts. 
Priority activities include HIV testing; linkage to, re-
engagement in, and retention in care and support for 
achieving viral suppression; support for pre-exposure 
prophylaxis (PrEP); community-level HIV prevention 
activities; and HIV transmission cluster investigations 
and outbreak response efforts. 
• Directly funding community-based organizations 
(CBOs) – to increase HIV testing, improve linkages to 
care and support improvement of viral suppression 
for persons living with HIV, and improve linkages to 
PrEP and other prevention services for persons who 
are at risk for HIV. 
• Providing technical assistance – to help health 
departments and CBOs develop the tools and
 skills to successfully implement effective HIV 
prevention activities for people living with HIV 
in their communities. 
• Improving surveillance capability and technology – 
to assist states in outbreak response and improving 
completeness of laboratory data that are needed to 
assess many of the steps in the HIV care continuum 
and the selected national HIV care outcomes. 
• Researching new approaches – to include studies 
of clinical, behavioral and structural interventions to 
help people with HIV stay in care, get back in care if 
they fall out of care, and adhere to their medications. 
• Developing guidelines – to assist health care 
providers with HIV testing, care, treatment, and 
prevention. 
• Launching educational campaigns and an HIV Risk 
Reduction Tool – to implement social marketing 
campaigns and provide educational resources; 
to help health care providers, at-risk populations, 
people with HIV, and the general public to reduce 
HIV stigma; increase HIV testing, prevention, and 
treatment; and understand risks for getting or 
transmitting HIV.
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Table 1: Calculating the Continuum:  Step by Step 
Continuum Step 
Diagnosed Measures the percentage of the total number of people living with HIV whose 
infection has been diagnosed. 
The denominator for this continuum step is HIV prevalence, which is the total  
number of people living with HIV (includes both those with diagnosed infection 
and those with undiagnosed infection). HIV prevalence is estimated through 
statistical modeling using National HIV Surveillance System (NHSS) data from  
all U.S. states and the District of Columbia (DC).  
Receipt of Care NHSS data from states and DC with complete reporting of CD4 and viral load test 
results are used to estimate “receipt of care” and “retained in care.” 
Receipt of care is measured as the percentage of persons with diagnosed HIV who 
had at least one CD4 or viral load test. 
The denominator for the prevalence-based continuum is all persons living with HIV 
(HIV prevalence). The denominator for the diagnosis-based continuum is all persons 
living with diagnosed HIV (diagnosed prevalence*). 
Retained in Care NHSS data from states and DC with complete reporting of CD4 and viral load test 
results are used to estimate “receipt of care” and “retained in care.” 
Retained in care is measured as the percentage of persons with diagnosed HIV  
who had two or more CD4 or viral load tests, performed at least three months apart. 
The denominator for the prevalence-based continuum is all persons living with HIV 
(HIV prevalence). The denominator for the diagnosis-based continuum is all persons 
living with diagnosed HIV (diagnosed prevalence*). 
Viral Suppression NHSS data from states and D.C. that have complete laboratory reporting are used 
to determine viral suppression. 
Viral suppression is measured as a viral load test result of <200 copies/mL at the 
most recent viral load test during measurement year. 
The denominator for the prevalence-based continuum is all persons living with HIV 
(HIV prevalence). The denominator for the diagnosis-based continuum is all persons 
living with diagnosed HIV (diagnosed prevalence*). 
Linked to Care NHSS data from states and DC with complete reporting of CD4 and viral load test 
results are used to determine “linked to care.” 
Linked to care measures the percentage of people receiving a diagnosis of HIV in a 
given calendar year who had one or more documented CD4 or viral load tests within 
30 days (1 month) of diagnosis. 
Because this measure is limited to people with HIV diagnosed in a single year, it 
cannot be directly compared to other steps in the continuum. This means that the 
denominator for linkage to care is different from the denominators used to calculate 
the other steps in the continuum. It is also important to note that an individual who 
enters care more than 30 days after diagnosis may still be included in subsequent 
steps of the continuum, but would not be counted as “linked to care.”
*Diagnosed prevalence is defined as the number of persons with HIV diagnosed through the end of 1 year and are living through the end of the
next year (e.g. diagnosed prevalence for 2016 is defined as persons receiving a diagnosis of HIV by end of 2015 and living through the end of 2016).
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